Early 2020: RIBOPRO was founded by scientists,
each with 10+ yrs of experience in mRNA and/or delivery. April 2020: first patent (on mRNA de-immunization methods) was filed. Febr. 2021: Seed financing of €1.3mio. Oct. 2021: Wellcome Leap R3-grant of €3.5mio to develop a
next-generation manufacturing device. Febr. 2022: 10x growth on virtually all parameters in 1 year. May 2022: 20th employee hired June 2022: Growth financing of €1mio (CLA) in preparation of a Series A. Q1 2023: Anticipated opening of GMP-manufacturing site in Maastricht.
RIBOPRO is rapidly growing through a combination of increasing sales (volume & order size), and well-controlled costs. We achieve cost control by backward integration of critical and costly raw materials (e.g. enzymes & custom lipids), automated manufacturing, and the use of smart software to minimize administrative burden. Through in-house R&D, we continuously find new and more efficient ways to approach manufacturing & other business processes.
Even more importantly, we are rapidly building a patent portfolio around key ingredients required for more advanced uses of mRNA, creating increasing licensing opportunities.
Revenues: 10x (’20-’21), 3x (’21-’22) from R&D-grade mfg. services Runway: until break-even mid ’23 => Looking for funding to accelerate Supply: Increasingly self-sufficient by in-house mfg. of raw materials Gross margin: >50% => >90% Growing pipeline for GMP-manufacturing (5-10x of R&D revenues) Licensing opportunities: >€10B expected from growing patent portfolio FTE: approaching 30
HQ: Pivot Park, Oss, the Netherlands – Production facility R&D-grade – Research laboratories (incl. BSL-2) – Offices
R3: Oss, the Netherlands – Engineering facility – Offices
GMP: Medace, Maastricht, the Netherlands – Production facility GMP-grade – Class A & C cleanrooms (ISO14644) – QC-laboratory – Microbiology lab (BSL-1)
Delivery technologies – Novel class of ionizable lipids – patented – Novel core lipid system => patent – Undisclosed technologies in development
Manufacturing technologies – Co-transcriptional capping method => patent – Novel RNAP variants with low dsRNA => patent – Novel DNA amplification method => patent – Undisclosed technologies in development
RIBOPRO is an innovative, premium CDMO and technology provider.
We provide the following products & services:
Core service: 1. mRNA design 2. de novo DNA template synthesis (via partners) 3. DNA cloning & amplification (in-house) 4. In vitro transcription (IVT), purification and modification of mRNA 5. LNP-formulation 6. Shipping (via partners)
Additional services: 1. Consultancy on experimental design/data 2. Consultancy on clinical trial design (coming in 2023) 3. CRO-services of specified assays (in-house) 4. GMP-manufacturing (coming in Q1 2023) 5. Out-licensing of technologies 6. Commercial-manufacturing (coming in 2024)
The additional services are provided to help customers reach the market/patient, thereby activating RIBOPRO’s royalties model.
RIBOPRO aims to raise €16.5mio for the following uses:
1. Increasing our speed (USP)
by shortening the turn-around of the de novo DNA step
2. Capturing market share a. Sample distribution (seeing is believing) b. Increased marketing c. Secondary facilities
3. Maintain/expand technology leadership a. mRNA tech R&D b. LNP tech R&D c. Special mRNA products d. Research collaborations e. IP-acquisitions
4. Data collection a. Pre-clinical (GLP) data package on proprietary products5. Micellaneous a. Develop the Byte-to-nucleotide(TM) platform b. Buffer
RIBOPRO is happy to have the following syndicate of investors for financial, strategic and practical support: 1. Stichting Vlasroot (business angel group) 2. BOM (regional investment fund) 3. Rockstart Health (VC) 4. Private investors
Comparison with competitive field
RIBOPRO uniquely operates at the cross-section of the contract drug manufacturing (CDMO) and technology provider fields. Therefore, we monitor market developments, and from time to time compare our performance/offering with competitors in both fields.
Below, we compare ourselves to the generalized competitor profiles from both fields to highlight the unique benefits that RIBOPRO can offer to customers by bringing both services under 1 roof. Of course, a more detailed competitor analysis is available upon request.
Focus on large-scale manufacturing sites with end-to-end mfg. Although beneficial for commercial and pandemic situations, these sites struggle to serve customers at the R&D-stage.
Large scale manufacturing
Knowledge, tech & mfg.
RIBOPRO is unique in its deep knowledge of mRNA and delivery, having its own patented technologies, and offering those technologies to the market in an one-stop-shop combination with state-of-the-art manufacturing.
R&D and GMP-grade mfg.
Short-term revenue from mfg
Long-term licensing revenue
Providing specialized technologies, e.g. ionizable lipids for LNP. mRNA medicines consist of multiple components, thus requiring multiple licenses/partners to complete a product.
Expertise at single technology
Exclusive licensing possible
The combination of low-risk income from manufacturing activities, with high-gain opportunities from licensing make RIBOPRO an attractive investment
Please bear with us while we get everything in order.
Importantly, we are ready to receive your order, quote request or meeting request as per usual.
We look forward helping you with the highest quality mRNA.